NCT06927635View on ClinicalTrials.gov

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2030

Conditions
Castrate Resistance Prostate CancerOligoProgressive Metastatic Disease
Interventions
RADIATION

Stereotactic Body Radiation Therapy (SBRT)

SBRT will be delivered as per institutional standard.

OTHER

Systemic therapy

Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Center, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT06927635 - Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer | Biotech Hunter | Biotech Hunter